m6A modification: recent advances, anticancer targeted drug discovery and beyond

作者：Lijuan Deng, Wei-Qing Deng, Shu-Ran Fan, Minfeng Chen, Ming Qi, Wen-Yu Lyu, Qi Qi, Amit Kumar Tiwari, Jiaxu Chen, Dongmei Zhang, Zhe‐Sheng Chen · 发表于：Molecular Cancer · 年份：2022 · DOI：10.1186/s12943-022-01510-2 · 被引用次数：387 · 研究领域：RNA modifications and cancer、Peptidase Inhibition and Analysis、HVDC Systems and Fault Protection

Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs. Three stages of m6A-targeting anticancer drug discovery: traditional medicine-based natural products, modern chemical modification or synthesis, and artificial intelligence (AI)-assisted approaches for the future.